28 results on '"Colafella, Katrina"'
Search Results
2. Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension.
- Author
-
Lucas, Sarah E., Walton, Sarah L., Mirabito Colafella, Katrina M., Mileto, Steven J., Lyras, Dena, and Denton, Kate M.
- Published
- 2023
- Full Text
- View/download PDF
3. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
- Author
-
van Doorn, Leni, Visser, Wesley J., van Dorst, Daan C. H., Mirabito Colafella, Katrina M., Koolen, Stijn L. W., de Mik, Anneke van Egmond-, Garrelds, Ingrid M., Bovée, Dominique M., de Hoop, Esther Oomen-, Bins, Sander, Eskens, Ferry A. L. M., Hoorn, Ewout J., Jan Danser, A. H., Mathijssen, Ron H. J., and Versmissen, Jorie
- Abstract
Background: Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension is sodium-sensitive in animal studies. Therefore, the efficacy of dietary sodium restriction (DSR) to prevent VEGFI-induced hypertension in cancer patients was studied.Methods: Cancer patients with VEGFI-induced hypertension (day mean >135/85 mmHg or a rise in systolic and/or diastolic BP ≥ 20 mmHg) were treated with DSR (aiming at <4 g salt/day). The primary endpoint was the difference in daytime mean arterial blood pressure (MAP) increase between the treatment cycle with and without DSR.Results: During the first VEGFI treatment cycle without DSR, mean daytime MAP increased from 95 to 110 mmHg. During the subsequent treatment cycle with DSR, mean daytime MAP increased from 94 to 102 mmHg. Therefore, DSR attenuated the increase in mean daytime MAP by 7 mmHg (95% CI 1.3-12.0, P = 0.009). DSR prevented the rise in the endothelin-1/renin ratio that normally accompanies VEGFI-induced hypertension (P = 0.020) and prevented the onset of proteinuria: 0.15 (0.10-0.25) g/24 h with DSR versus 0.19 (0.11-0.32) g/24 h without DSR; P = 0.005.Discussion: DSR significantly attenuated VEGFI induced BP rise and proteinuria and thus is an effective non-pharmacological intervention. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease.
- Author
-
Cruz-López, Edwyn O., Ye, Dien, Wu, Congqing, Lu, Hong S., Uijl, Estrellita, Mirabito Colafella, Katrina M., and Danser, A.H. Jan
- Published
- 2022
- Full Text
- View/download PDF
5. Highlights from the International Society of Hypertension's New Investigators Network during 2019.
- Author
-
Kruger, Ruan, Brunström, Mattias, Burger, Dylan, Charchar, Fadi, Climie, Rachel, Colafella, Katrina M. Mirabito, Kempny, Pablo, Korostovtseva, Lyudmila, Marques, Francine Z., Picone, Dean, Romero, Cesar, Steckelings, Ulrike M., Velkoska, Elena, Wainford, Richard, Wynne, Brandi M., Zanuzzi, Matias G., and Mirabito Colafella, Katrina M
- Published
- 2020
- Full Text
- View/download PDF
6. The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials.
- Author
-
Schreuder, Michelle M., Mirabito Colafella, Katrina M., Boersma, Eric, Brugts, Jasper J., Roeters van Lennep, Jeanine E., and Versmissen, Jorie
- Subjects
SYSTOLIC blood pressure ,RENIN-angiotensin system ,DIASTOLIC blood pressure ,BLOOD pressure ,OLDER men - Abstract
Previous studies showed that postmenopausal women are more likely to have poorly controlled hypertension than men of the same age. Whether this is caused by inadequate treatment or poor response to antihypertensive agents remains unknown. The aim of this study is to analyze treatment response to the most potent renin angiotensin aldosterone system (RAAS) inhibitor perindopril in different age categories in women and men. Individual patient data were used from the combined European Trial on Reduction of Cardiac Events With Perindopril (EUROPA), Perindopril Protection Against Recurrent Stroke Study (PROGRESS), and Action in Diabetes and Vascular disease: Preterax and Diamicron‐MR Controlled Evaluation (ADVANCE) trials, which include patients with vascular disease (n = 29,463). We studied the relative and absolute changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) during a 4‐week run‐in phase in which all patients were treated with the perindopril‐based treatment in different age categories. In total, 8366 women and 21,097 men were included in the analysis. Women greater than 65 years of age showed a significantly smaller blood pressure reduction after perindopril treatment (2.8 mmHg [95% confidence interval {CI} = 0.1–5.5] less reduction compared to women ≤45 years, p = 0.039). In men, the SBP reduction after perindopril in patients greater than 55–65 and greater than 65 years was lower compared to the age category less than or equal to 45 years (adjusted mean difference >55–65: 2.8 mmHg [95% CI = 1.8–3.7], p < 0.001, >65: 3.7 mmHg [95% CI = 2.7–4.7], p < 0.001). A trend of less blood pressure reduction was seen with ageing in both men and women (p < 0.001). To conclude, we observed that in both women and men the perindopril leads to less SBP reduction with increasing age, whereas the DBP reduction increases with age. More research is needed to determine whether it would be beneficial to use age‐adjusted perindopril dosages. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
- Author
-
van Dorst, Daan C. H., van Doorn, Leni, Colafella, Katrina M. Mirabito, Manintveld, Olivier C., Hassing, H. Carlijne Hassing, Danser, A. H. Jan, Mathijssen, Ron H. J., and Versmissen, Jorie
- Subjects
IMMUNE checkpoint inhibitors ,VASCULAR endothelial growth factor antagonists ,NEOVASCULARIZATION inhibitors ,CARDIOTOXICITY ,CONGESTIVE heart failure - Abstract
In the past two decades, treatment outcomes for a wide range of malignancies have improved remarkably due to the development of novel anti-cancer therapies, including vascular endothelial growth factor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs). Despite their unprecedented anti-tumour effects, it is becoming increasingly clear that both types of agents are associated with specific cardiovascular toxicity, including hypertension, congestive heart failure, myocarditis and acceleration of atherosclerosis. Currently, VEGFI and ICI combination therapy is recommended for the treatment of advanced renal cell carcinoma (RCC) and has shown promising treatment efficacy in other tumour types as well. Consequently, VEGFI and ICI combination therapy will most likely become an important therapeutic strategy for various malignancies. However, this combinatory approach is expected to be accompanied by a substantial increase in cardiovascular risk, as both types of agents could act synergistically to induce cardiovascular sequelae. Therefore, a comprehensive baseline assessment and adequate monitoring by specialised cardio-oncology teams is essential in case these agents are used in combination, particularly in high-risk patients. This review summarises the mechanisms of action and treatment indications for currently registered VEGFIs and ICIs, and discusses their main vascular and cardiac toxicity. Subsequently, we provide the biological rationales for the observed promising synergistic anti-tumour effects of combined VEGFI/ICI administration. Lastly, we speculate on the increased risk for cardiovascular toxicity in case these agents are used in combination and its implications and future directions for the clinical situation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. In Aged Females, the Enhanced Pressor Response to Angiotensin II Is Attenuated By Estrogen Replacement via an Angiotensin Type 2 Receptor-Mediated Mechanism.
- Author
-
Barsha, Giannie, Mirabito Colafella, Katrina M., Walton, Sarah L., Gaspari, Tracey A., Spizzo, Iresha, Pinar, Anita A., Hilliard Krause, Lucinda M., Widdop, Robert E., Samuel, Chrishan S., and Denton, Kate M.
- Published
- 2021
- Full Text
- View/download PDF
9. Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia.
- Author
-
van Aanhold, Cleo C. L., Bos, Manon, Mirabito Colafella, Katrina M., van der Hoorn, Marie-Louise P., Wolterbeek, Ron, Bruijn, Jan A., Bloemenkamp, Kitty W. M., van den Meiracker, Anton H., Danser, A. H. Jan, and Baelde, Hans J.
- Subjects
THROMBOMODULIN ,PREECLAMPSIA ,APOPTOSIS ,BLOOD coagulation ,BLOOD serum analysis - Abstract
The endothelial glycoprotein thrombomodulin regulates coagulation, vascular inflammation and apoptosis. In the kidney, thrombomodulin protects the glomerular filtration barrier by eliciting crosstalk between the glomerular endothelium and podocytes. Several glomerular pathologies are characterized by a loss of glomerular thrombomodulin. In women with pre-eclampsia, serum levels of soluble thrombomodulin are increased, possibly reflecting a loss from the glomerular endothelium. We set out to investigate whether thrombomodulin expression is decreased in the kidneys of women with pre-eclampsia and rats exposed to an angiogenesis inhibitor. Thrombomodulin expression was examined using immunohistochemistry and qPCR in renal autopsy tissues collected from 11 pre-eclamptic women, 22 pregnant controls and 11 hypertensive non-pregnant women. Further, kidneys from rats treated with increasing doses of sunitinib or sunitinib in combination with endothelin receptor antagonists were studied. Glomerular thrombomodulin protein levels were increased in the kidneys of women with pre-eclampsia. In parallel, in rats exposed to sunitinib, glomerular thrombomodulin was upregulated in a dose-dependent manner, and the upregulation of glomerular thrombomodulin preceded the onset of histopathological changes. Selective ET
A R blockade, but not dual ETA/B R blockade, normalised the sunitinib-induced increase in thrombomodulin expression and albuminuria. We propose that glomerular thrombomodulin expression increases at an early stage of renal damage induced by antiangiogenic conditions. The upregulation of this nephroprotective protein in glomerular endothelial cells might serve as a mechanism to protect the glomerular filtration barrier in pre-eclampsia. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.
- Author
-
Uijl, Estrellita, Ren, Liwei, Colafella, Katrina M. Mirabito, van Veghel, Richard, Garrelds, Ingrid M., Domenig, Oliver, Poglitsch, Marko, Zlatev, Ivan, Kim, Jae B., Huang, Stephen, Melton, Lauren, Hoorn, Ewout J., Foster, Don, and Danser, A. H. Jan
- Subjects
RENIN-angiotensin system ,ANGIOTENSIN II ,HYPERTENSION ,ANGIOTENSINOGEN ,ANGIOTENSINS - Abstract
Brain renin-angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n = 6-8/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by Western blotting, and angiotensin metabolites by LC-MS/MS. In rats without DOCA-salt, circulating angiotensin IIwas detected in all rats, whereas brainstem angiotensin IIwas detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19+- 1 mmHg and suppressed circulating renin and angiotensin II by>90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (<6 fmol/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97+-0.3%, and made brainstem angiotensin II undetectable in all rats (P<0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Insulin-regulated aminopeptidase deficiency impairs cardiovascular adaptations and placental development during pregnancy.
- Author
-
Walton, Sarah L., Mirabito Colafella, Katrina M., Ansari, Aneesa, Siew Yeen Chai, and Denton, Kate M.
- Subjects
DRINKING (Physiology) ,PREGNANCY ,HEART beat ,KNOCKOUT mice ,RADIO telemetry - Abstract
Insulin-regulated aminopeptidase (IRAP), an enzyme that cleaves vasoactive peptides including oxytocin and vasopressin, is suggested to play a role in pregnancy and the onset of preeclampsia. Our aim was to examine the contribution of IRAP to arterial pressure regulation and placental development during pregnancy in mice. Mean arterial pressure and heart rate were measured via radiotelemetry in 12-week-old female wild-type and IRAP knockout mice. Females were time-mated withmales of the same genotype. Placentae were collected at embryonic day 18.5 for histological analysis. Basal heart rate was ~40 bpm lower in IRAP knockout females compared with wild-type females. The increase in heart rate across gestation was greater in IRAP knockout females than wild-type females. Neither basal nor gestational mean arterial pressure was different between wildtype and IRAP knockout females. Urine output and water intake of IRAP knockout mice were ~45% less than wild-type mice at late gestation. IRAP deficiency had no effect on fetal weight. Morphological assessment of placentae revealed that IRAP deficiency was associated with reduced labyrinth surface area and accumulation of glycogen in the junctional zone. Our data demonstrate that IRAP deficiency alters maternal fluid handling and impairs placental labyrinth expansion at late gestation, indicating that IRAP contributes to the normal adaptions to pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms.
- Author
-
Bovee, Dominique M., Cuevas, Catharina A., Zietse, Robert, Danser, A. H. Jan, Colafella, Katrina M. Mirabito, and Hoorn, Ewout J.
- Subjects
CHRONIC kidney failure ,ALDOSTERONE antagonists ,RENIN-angiotensin system ,T helper cells ,ANGIOTENSIN II ,MINERALOCORTICOID receptors ,INFLAMMATION - Abstract
Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms. Am J Physiol Renal Physiol 319: F729-F745, 2020. First published September 28, 2020; doi:10.1152/ajprenal.00407.2020.--Chronic kidney disease (CKD) causes salt-sensitive hypertension that is often resistant to treatment and contributes to the progression of kidney injury and cardiovascular disease. A better understanding of the mechanisms contributing to salt-sensitive hypertension in CKD is essential to improve these outcomes. This review critically explores these mechanisms by focusing on how CKD affects distal nephron Na+ reabsorption. CKD causes glomerulotubular imbalance with reduced proximal Na+ reabsorption and increased distal Na+ delivery and reabsorption. Aldosterone secretion further contributes to distal Na+ reabsorption in CKD and is not only mediated by renin and K+ but also by metabolic acidosis, endothelin-1, and vasopressin. CKD also activates the intrarenal renin-angiotensin system, generating intratubular angiotensin II to promote distal Na+ reabsorption. High dietary Na+ intake in CKD contributes to Na+ retention by aldosterone-independent activation of the mineralocorticoid receptor mediated through Rac1. High dietary Na+ also produces an inflammatory response mediated by T helper 17 cells and cytokines increasing distal Na+ transport. CKD is often accompanied by proteinuria, which contains plasmin capable of activating the epithelial Na+ channel. Thus, CKD causes both local and systemic changes that together promote distal nephron Na+ reabsorption and salt-sensitive hypertension. Future studies should address remaining knowledge gaps, including the relative contribution of each mechanism, the influence of sex, differences between stages and etiologies of CKD, and the clinical relevance of experimentally identified mechanisms. Several pathways offer opportunities for intervention, including with dietary Na+ reduction, distal diuretics, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, and K+ or H+ binders. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
- Author
-
Colafella, Katrina M Mirabito, Neves, Karla B, Montezano, Augusto C, Garrelds, Ingrid M, Veghel, Richard van, Vries, René de, Uijl, Estrellita, Baelde, Hans J, Meiracker, Anton H van den, Touyz, Rhian M, Danser, A H Jan, and Versmissen, Jorie
- Subjects
ALBUMINURIA ,NEPHROTOXICOLOGY ,CARDIOTOXICITY ,HYPERTENSION ,NEOVASCULARIZATION inhibitors - Abstract
Aims Although effective in preventing tumour growth, angiogenesis inhibitors cause off-target effects including cardiovascular toxicity and renal injury, most likely via endothelin (ET)-1 up-regulation. ET-1 via stimulation of the ET
A receptor has pro-hypertensive actions whereas stimulation of the ETB receptor can elicit both pro- or anti-hypertensive effects. In this study, our aim was to determine the efficacy of selective ETA vs. dual ETA/B receptor blockade for the prevention of angiogenesis inhibitor-induced hypertension and albuminuria. Methods and results Male Wistar Kyoto (WKY) rats were treated with vehicle, sunitinib (angiogenesis inhibitor; 14 mg/kg/day) alone or in combination with macitentan (ETA/B receptor antagonist; 30 mg/kg/day) or sitaxentan (selective ETA receptor antagonist; 30 or 100 mg/kg/day) for 8 days. Compared with vehicle, sunitinib treatment caused a rapid and sustained increase in mean arterial pressure of ∼25 mmHg. Co-treatment with macitentan or sitaxentan abolished the pressor response to sunitinib. Sunitinib did not induce endothelial dysfunction. However, it was associated with increased aortic, mesenteric, and renal oxidative stress, an effect that was absent in mesenteric arteries of the macitentan and sitaxentan co-treated groups. Albuminuria was greater in the sunitinib- than vehicle-treated group. Co-treatment with sitaxentan, but not macitentan, prevented this increase in albuminuria. Sunitinib treatment increased circulating and urinary prostacyclin levels and had no effect on thromboxane levels. These increases in prostacyclin were blunted by co-treatment with sitaxentan. Conclusions Our results demonstrate that both selective ETA and dual ETA/B receptor antagonism prevents sunitinib-induced hypertension, whereas sunitinib-induced albuminuria was only prevented by selective ETA receptor antagonism. In addition, our results uncover a role for prostacyclin in the development of these effects. In conclusion, selective ETA receptor antagonism is sufficient for the prevention of sunitinib-induced hypertension and renal injury. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Aspirin for the prevention and treatment of pre‐eclampsia: A matter of COX‐1 and/or COX‐2 inhibition?
- Author
-
Mirabito Colafella, Katrina M., Neuman, Rugina I., Visser, Willy, Danser, A. H. Jan, and Versmissen, Jorie
- Subjects
ASPIRIN ,PREECLAMPSIA ,CYCLOOXYGENASES ,PATHOLOGY - Abstract
Since the 1970s, we have known that aspirin can reduce the risk of pre‐eclampsia. However, the underlying mechanisms explaining this risk reduction are poorly understood. Both cyclooxygenase (COX)‐1‐ and COX‐2‐dependent effects might be involved. As a consequence of this knowledge hiatus, the optimal dose and timing of initiation of aspirin therapy are not clear. Here, we review how (COX‐1 versus COX‐2 inhibition) and when (prevention versus treatment) aspirin therapy may interfere with the mechanisms implicated in the pathogenesis of pre‐eclampsia. The available evidence suggests that both COX‐1‐ and COX‐2‐dependent effects play important roles in the early stage of aberrant placental development and in the next phase leading to the clinical syndrome of pre‐eclampsia. Collectively, these data suggest that high‐dose (dual COX inhibition) aspirin may be superior to standard low‐dose (selective COX‐1 inhibition) aspirin for the prevention and also treatment of pre‐eclampsia. Therefore, we conclude that more functional and biochemical tests are needed to unravel the contribution of prostanoids in the mechanisms implicated in the pathogenesis of pre‐eclampsia and the potential of dual COX and/or selective COX‐2 inhibition for the prevention and treatment of pre‐eclampsia. This information is vital if we are to deduce the suitability, optimal timing and dose of aspirin and/or a specific COX‐2 inhibitor (most likely using modified forms that do not cross the placenta) that can then be tested in a randomized, controlled trial instead of the current practice of empirical dosing regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Targeting angiotensinogen with RNA-based therapeutics.
- Author
-
Liwei Ren, Colafella, Katrina M. Mirabito, Bovée, Dominique M., Uijl, Estrellita, Danser, A. H. Jan, and Ren, Liwei
- Published
- 2020
- Full Text
- View/download PDF
16. Endothelin receptor antagonism during preeclampsia: a matter of timing?
- Author
-
Hitzerd, Emilie, Neuman, Rugina I., Colafella, Katrina M. Mirabito, Reiss, Irwin K. M., van den Meiracker, Anton H., Danser, A. H. Jan, Visser, Willy, Versmissen, Jorie, and Saleh, Langeza
- Subjects
ENDOTHELIN receptors ,ABORTION ,PREGNANCY complications ,PREECLAMPSIA ,FETAL abnormalities ,HUMAN abnormalities - Abstract
Preeclampsia (PE) is a pregnancy complication, featuring elevated blood pressure and proteinuria, with no appropriate treatment. Activation of the endothelin system has emerged as an important pathway in PE pathophysiology based on experimental PE models where endothelin receptor antagonists (ERAs) prevented or attenuated hypertension and proteinuria. Hence, ERAs have been suggested as potential therapy for PE. However, developmental toxicity studies in animals have shown severe teratogenic effects of ERAs, particularly craniofacial malformations. Nonetheless, sporadic cases of pregnancy in women using ERAs to treat pulmonary hypertension have been described. In this review we give an overview of cases describing ERA use in pregnancy and critically address their possible teratogenic effects. A systematic search in literature yielded 18 articles describing 39 cases with ERA exposure during human pregnancy. Inmost cases there was only exposure in the first trimester, but exposure later or throughout pregnancy was reported in five cases. Elective termination of pregnancy was performed in 12 pregnancies (31%), two ended in a spontaneous miscarriage (5%) and no fetal congenital abnormalities have been described in the remaining cases. These preliminary findings support the idea that ERA treatment for severe, early onset PE might be an option if applied later in pregnancy, when organogenesis is completed to avoid teratogenic risks. However, third trimester toxicology studies are warranted to evaluate drug safety. Subsequently, it remains to be established whether ERA treatment is effective for alleviatingmaternal symptoms, as demonstrated in preclinical PE models, allowing pregnancy prolongation without leading to adverse neonatal outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.
- Author
-
Uijl, Estrellita, Mirabito Colafella, Katrina M., Sun, Yuan, Ren, Liwei, van Veghel, Richard, Garrelds, Ingrid M., de Vries, René, Poglitsch, Marko, Zlatev, Ivan, Kim, Jae B., Hoorn, Ewout J., Foster, Don, and Danser, A.H. Jan
- Published
- 2019
- Full Text
- View/download PDF
18. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
- Author
-
Versmissen, Jorie, Colafella, Katrina M Mirabito, Koolen, Stijn L W, and Danser, A H Jan
- Subjects
ASPIRIN ,VASCULAR endothelial growth factors ,THYROID cancer ,DRUG side effects ,DRUG monitoring ,RENAL cell carcinoma ,PREGNANCY complications ,RENIN-angiotensin system - Abstract
Since the formation of new blood vessels is essential for tumour growth and metastatic spread, inhibition of angiogenesis by targeting the vascular endothelial growth factor (VEGF) pathway is an effective strategy for various types of cancer, most importantly renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. However, VEGF inhibitors have serious side effects, most importantly hypertension and nephropathy. In case of fulminant hypertension, this may only be handled by lowering the dosage since the blood pressure rise is proportional to the amount of VEGF inhibition. These effects pathophysiologically and clinically resemble the most severe complication of pregnancy, preeclampsia, in which case an insufficient placenta leads to a rise in sFlt-1 levels causing a decrease in VEGF availability. Due to this overlap, studies in preeclampsia may provide important information for VEGF inhibitor-induced toxicity and vice versa. In both VEGF inhibitor-induced toxicity and preeclampsia, endothelin (ET)-1 appears to be a pivotal player. In this review, after briefly summarizing the anticancer effects, we discuss the mechanisms that potentially underlie the unwanted effects of VEGF inhibitors, focusing on ET-1, nitric oxide and oxidative stress, the renin–angiotensin–aldosterone system, and rarefaction. Given the salt sensitivity of this phenomenon, as well as the beneficial effects of aspirin in preeclampsia and cancer, we next provide novel treatment options for VEGF inhibitor-induced toxicity, including salt restriction, ET receptor blockade, and cyclo-oxygenase inhibition, in addition to classical antihypertensive and renoprotective drugs. We conclude with the recommendation of therapeutic drug monitoring to improve patient outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?
- Author
-
Colafella, Katrina M. Mirabito
- Subjects
CARDIOVASCULAR diseases risk factors ,ENDOTHELINS ,ECLAMPSIA ,CLINICAL trials ,WOMEN'S health - Abstract
In a recent issue of Clinical Science, Stanhewicz et al. investigated persistent microvascular dysfunction in women up to 16 months postpartum. The authors found sensitivity to the pressor effects of endothelin-1 (ET-1) was enhanced when compared with women who had a normotensive pregnancy. Importantly, the authors demonstrated that this effect was mediated via the endothelin type B (ET
B ) receptors. Therefore, the present study highlights the possibility that alterations in the localization of the ETB receptor contributes to the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk. Currently, there is great interest in the role of the endothelin system in pre-eclampsia. Targetting the endothelin system, potentially by modulating upstream pathways to prevent ETB receptor dysfunction, may improve health outcomes for women and their offspring during pre-eclampsia and later life. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. Relaxin contributes to the regulation of arterial pressure in adult female mice.
- Author
-
Mirabito Colafella, Katrina M., Samuel, Chrishan S., and Denton, Kate M.
- Abstract
Relaxin is increasingly being recognized as a potent vasodilatory and antifibrotic hormone. Given that relaxin is present in the circulation during the luteal phase of the menstrual cycle and during pregnancy, when arterial pressure is lowest in women, relaxin may contribute to the relative cardiovascular protection observed in premenopausal women as compared with age-matched men and postmenopausal women. In the present study, we investigated the contribution of relaxin to the normal regulation of arterial pressure in adult female and male mice and during pregnancy. Mean arterial pressure (MAP) was measured via radiotelemetry in 14-week-old male and female wild-type (WT; C67BL/6xSv129) and relaxin knockout (KO) mice. Thereafter, female mice were time-mated with a (non-telemetered) male of the same genotype and MAP was measured throughout gestation. Basal MAP was ∼10 mmHg lower in WT females than males (P<0.05). Relaxin deficiency increased basal MAP in females (P<0.05 vs WT female), but not males. As expected, MAP decreased during gestation in WT mice. Conversely, in relaxin KO mice, arterial pressure increased during mid and late gestation (P<0.05 as compared with WT). Moreover, relaxin deficiency impaired gestational weight gain and reduced litter size. This is the first study to (i) demonstrate that relaxin contributes to the sexual dimorphism of arterial pressure in mice and (ii) document the changes in the arterial pressure profile of pregnant relaxin KO mice. Understanding the mechanisms that underlie the regulation of arterial pressure in premenopausal females may uncover new strategies to treat hypertension in women (non-pregnant and pregnant) and men. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Recent Advances in Angiotensin Research.
- Author
-
Mirabito Colafella, Katrina M. and Jan Danser, A. H.
- Published
- 2017
- Full Text
- View/download PDF
22. The protective effect of apolipoprotein in models of trophoblast invasion and preeclampsia.
- Author
-
Charlton, Francesca, Bobek, X. Gabriele, Stait-Gardner, Tim, Price, William S., Mirabito Colafella, Katrina M., Bei Xu, Makris, Angela, Rye, Kerry-Anne, and Hennessy, Annemarie
- Subjects
APOLIPOPROTEIN A ,PREECLAMPSIA ,PREGNANCY complications ,THERAPEUTICS - Abstract
Preeclampsia is a hypertensive disorder of pregnancy. It is associated with abnormal placentation via poor placental invasion of the uterine vasculature by trophoblast cells, leading to poor placental perfusion, oxidative stress, and inflammation, all of which are implicated in its pathogenesis. A dyslipidemia characterized by low plasma levels of high-density lipoproteins (HDL) and elevated triglycerides has been described in preeclampsia. Apolipoprotein A-I (apoA-I), a constituent of HDL is an anti-inflammatory agent. This study investigated whether apoA-I protects against hypertension and adverse placental changes in a proinflammatory cytokine (TNF-α)-induced model of preeclampsia. Further, this study investigated whether apoA-I protects against the inhibitory effect of TNF-α in a human in vitro model of trophoblast invasion. Administration of apoA-I to pregnant mice before infusion with TNF-α resulted in a significant reduction in the cytokine-induced increase in systolic blood pressure. MRI measurement of T
2 relaxation, a parameter that is tissue specific and sensitive to physiological changes within tissues, showed a reversal of TNF-α-induced placental changes. Preincubation of endothelial cells with apoA-I protected against the TNF-α-induced inhibition of HTR-8/SVneo (trophoblast) cell integration into endothelial (UtMVEC) networks. These data suggest that a healthy lipid profile may affect pregnancy outcomes by priming endothelial cells in preparation for trophoblast invasion. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. Sex- and age-related differences in arterial pressure and albuminuria in mice.
- Author
-
Barsha, Giannie, Denton, Kate M., and Colafella, Katrina M. Mirabito
- Subjects
ALBUMINURIA ,LABORATORY mice ,CIRCADIAN rhythms - Abstract
Background: Animal models have become valuable experimental tools for understanding the pathophysiology and therapeutic interventions in cardiovascular disease. Yet to date, few studies document the age- and sex-related differences in arterial pressure, circadian rhythm, and renal function in normotensive mice under basal conditions, across the life span. We hypothesized that mice display similar sex- and age-related differences in arterial pressure and renal function to humans. Methods: Mean arterial pressure (MAP) and circadian rhythm of arterial pressure were measured over 3 days via radiotelemetry, in 3- and 5-month-old (adult) and 14- and 18-month-old (aged) FVB/N and in 5-month-old (adult) C57BL/6 male and female normotensive mice. In FVB/N mice, albuminuria from 24-h urine samples as well as body, heart, and kidney weights were measured at each age. Results: Twenty-four-hour MAP was greater in males than females at 3, 5, and 14 months of age. A similar sex difference in arterial pressure was observed in C57BL/6 mice at 5 months of age. In FVB/N mice, 24-h MAP increased with age, with females displaying a greater increase between 3 and 18 months of age than males, such that MAP was no longer different between the sexes at 18 months of age. A circadian pattern was observed in arterial pressure, heart rate, and locomotor activity, with values for each greater during the active (night/dark) than the inactive (day/light) period. The night-day dip in MAP was greater in males and increased with age in both sexes. Albuminuria was greater in males than females, increased with age in both sexes, and rose to a greater level in males than females at 18 months of age. Conclusions: Arterial pressure and albuminuria increase in an age- and sex-specific manner in mice, similar to patterns observed in humans. Thus, mice represent a useful model for studying age and sex differences in the regulation of arterial pressure and renal disease. Understanding the mechanisms that underlie the pathophysiology of cardiovascular disease may lead to new and better-tailored therapies for men and women. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Epochs in the depressor/pressor balance of the renin-angiotensin system.
- Author
-
Colafella, Katrina M. Mirabito, Hilliard, Lucinda M., and Denton, Kate M.
- Subjects
RENIN-angiotensin system ,EXTRACELLULAR fluid ,ANGIOTENSINS ,KIDNEY diseases ,ANGIOTENSIN I - Abstract
The renin-angiotensin system (RAS) plays a commanding role in the regulation of extracellular fluid homoeostasis. Tigerstadt and Bergman first identified the RAS more than two centuries ago. By the 1980s a voyage of research and discovery into the mechanisms and actions of this system led to the development of drugs that block the RAS, which have become the mainstay for the treatment of cardiovascular and renal disease. In the last 25 years new components of the RAS have come to light, including the angiotensin type 2 receptor (AT
2 R) and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7) [Ang(1-7)]/Mas receptor (MasR) axis. These have been shown to counter the classical actions of angiotensin II (AngII) at the predominant angiotensin type 1 receptor (AT1R). Our studies, and those of others, have demonstrated that targeting these depressor RAS pathways may be therapeutically beneficial. It is apparent that the evolution of both the pressor and depressor RAS pathways is distinct throughout life and that the depressor/pressor balance of the RAS vary between the sexes. These temporal patterns of expression suggest that therapies targeting the RAS could be optimized for discrete epochs in life. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
25. CYCLOOXYGENASE-2 INHIBITION AS A NEW TOOL TO COMBAT ANGIOGENESIS INHIBITOR-INDUCED HYPERTENSION AND RENAL TOXICITY.
- Author
-
Van Dorst, Daan, Colafella, Katrina Mirabito, Van Doorn, Leni, Van Veghel, Richard, Garrelds, Ingrid, Mathijssen, Ron, Danser, Jan, and Versmissen, Jorie
- Published
- 2022
- Full Text
- View/download PDF
26. Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy.
- Author
-
Versmissen, Jorie, van Doorn, Leni, Colafella, Katrina M. Mirabito, Mathijssen, Ron H., Danser, A. H. Jan, and Mirabito Colafella, Katrina M
- Published
- 2018
- Full Text
- View/download PDF
27. Recent Advances in Angiotensin Research.
- Author
-
Mirabito Colafella, Katrina M and Danser, A H Jan
- Published
- 2017
- Full Text
- View/download PDF
28. Chronic recurrent dehydration associated with periodic water intake exacerbates hypertension and promotes renal damage in male spontaneously hypertensive rats.
- Author
-
Hilliard, Lucinda M., Colafella, Katrina M. Mirabito, Bulmer, Louise L., Puelles, Victor G., Singh, Reetu R., Ow, Connie P. C., Gaspari, Tracey, Drummond, Grant R., Evans, Roger G., Vinh, Antony, and Denton, Kate M.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.